NCT07841925
A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors
StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Start date changed from estimate of Sep 2026 to Oct 13, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Recommended Phase II Dose (RP2D)
Timeframe: Up to approximately 24 months
Objective Response Rate (ORR)
Timeframe: Up to approximately 24 months
Secondary (11)
Progression-free Survival (PFS)
Disease Control Rate (DCR)
Duration of Response (DOR)
Treatment-Emergent Adverse Event (TEAE)
Cmax
Show 6 moreShow less
Tmax
T1/2
AUC0-t
CL (Clearance)
Ctrough
Anti-drug Antibody (ADA)
Arms and interventions
BL-M08D1Experimental
Participants receive BL-M08D1 for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Drugs: BL-M08D1
Sites
1 site in 1 country
- Beijing Cancer HospitalBeijing, Beijing Municipality, China